GlassScriptPhysician profile
Sonia Bajaj
NPI 1255327789
$10,437.43
in general payments reported to CMS, 2019-2025
24 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $1,102 · 2021: $1,155 · 2022: $1,795 · 2023: $2,035 · 2024: $1,531 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,251 · Education: $37.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,251.22 |
| Education | $37.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,457.45 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $2,291.76 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $936.93 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $899.47 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $600.76 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $513.79 | 2019-2025 | Tremfya |
| Pfizer INC. | $443.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $419.22 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $310.51 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $297.26 | 2019-2023 | |
| Lilly USA, LLC | $277.87 | 2020-2023 | Taltz |
| Genentech USA, INC. | $167.04 | 2019-2024 | Actemra, Rituxan |
| Aurinia Pharma U.S., INC. | $154.21 | 2022-2023 | Lupkynis |
| Johnson & Johnson Health Care Systems INC. | $150.00 | 2024 | Tremfya |
| Sandoz INC. | $113.35 | 2023-2025 | Hyrimoz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $86.74 | 2019-2023 | |
| Celgene Corporation | $70.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.57 | 2019-2023 | Cyltezo |
| Radius Health, INC. | $45.11 | 2019 | |
| Celltrion USA INC. | $37.79 | 2023 | Yuflyma |
| Alexion Pharmaceuticals, INC. | $29.65 | 2025 | Strensiq |
| Octapharma USA, INC. | $25.70 | 2022 | |
| Ani Pharmaceuticals, INC. | $24.70 | 2023 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $20.09 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.